MAPS & ITEC Cohorts: 6-8 Years Follow-up

• Status: Completed
• Trial end date: 2019-01-15
• Target enrollment: 0
• Participant gender: All

Summary

This study represents the follow-up, age 6-8 years, of children recruited at birth into two cohorts. The first cohort, the Mite Allergen Prevention Study (MAPS) was a double-blind, randomized controlled trial of the use of house dust-mite immunotherapy in the primary prevention of atopy and asthma. The Immune Tolerance in Early Childhood (ITEC) cohort is a separate observational cohort following up infants at high risk of atopy and correlating atopic disease development with epigenetic markers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Southampton
• Collaborator: Isle of Wight NHS Trust

Criteria

Inclusion Criteria:

•Inclusion in original study cohorts at birth

•≥2 first-degree relatives with allergic disease (food allergy, asthma, eczema, rhinoconjunctivitis)

Exclusion Criteria:

• Not included in the original study cohorts

• Skin-prick test positive to any allergen (HDM, cat, grass pollen, peanut, egg and milk) age 5 months